Premium
UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL
Author(s) -
Davids M.S.,
Kim H.T.,
Nicotra A.,
Savell A.,
Francoeur K.,
Hellman J.M.,
Miskin H.,
Sportelli P.,
Bashey A.,
Stampleman L.,
Rueter J.,
Boruchov A.,
Arnason J.E.,
Jacobson C.A.,
Jacobsen E.J.,
Fisher D.C.,
Brown J.R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_39
Subject(s) - ibrutinib , medicine , tolerability , refractory (planetary science) , bruton's tyrosine kinase , oncology , neutropenia , phases of clinical research , clinical trial , toxicity , adverse effect , chronic lymphocytic leukemia , leukemia , tyrosine kinase , physics , receptor , astrobiology